Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Amit Sanyal, MD: A Clinician’s Perspective

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Advertisement

Advertisement




Jan
24
Today In Oncology
Genomic Classifier Tests May Influence Treatment Decisions in Prostate Cancer Despite Lack of Evidence for Long Term Outcomes
Effect of KRAS Mutation Status on Treatment Outcomes in Metastatic Pancreatic Adenocarcinoma
Talquetamab Plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Telephone Based Therapy May Reduce Fatigue Interference With Functioning in Metastatic Breast Cancer Survivors
Imlunestrant Alone or With Abemaciclib An All-Oral Targeted Therapy for ER-Positive Advanced Breast Cancer
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo